CollaGenex' Oracea Rosacea Therapy Could Launch Third Quarter 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm announces NDA submission for the rosacea therapy. As the first oral systemic rosacea treatment, Oracea could expand the market, CollaGenex says.
You may also be interested in...
CollaGenex Will Launch Oracea In July With Specialty Sales Force
Oracea cleared FDA as the first orally administered, systemically delivered drug to treat rosacea.
CollaGenex Will Launch Oracea In July With Specialty Sales Force
Oracea cleared FDA as the first orally administered, systemically delivered drug to treat rosacea.
FDA Approves Periostat Generics, But Launch Could Hinge On Patent Case
FDA approves three ANDAs for Periostat tablets and one for the capsule formulation. In a patent infringement lawsuit, Periostat marketer CollaGenex is requesting that a federal court preliminarily enjoin launches by Ivax and CorePharma.